CXCR4 and Miyoshi myopathy: GMI-1359, developed by GlycoMimetics, is a dual inhibitor of CXCR4 and E-selectin that promotes leukemic cells mobilization to peripheral blood in AML and extended survival in PDX models [19], as well as in preclinical models of MM [172].